Chadwick Jeremy G
SEC CIK 1388406 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | COO | 44.0K | — | $15.81M | 19 | 2023-05-22 | 2026-05-26 |
Most active insiders at KYMR, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Booth Bruce | Dir | — | $226.03M |
| 2 | BVF PARTNERS L P/IL | Dir, See Remarks, Footnotes | — | $173.67M |
| 3 | BAKER FELIX | Dir, 10% | $172.50M | — |
| 4 | Mainolfi Nello | CEO, Dir | — | $33.41M |
| 5 | Chadwick Jeremy G | COO | — | $15.60M |
| 6 | Jacobs Bruce N. | CFO | — | $9.96M |
| 7 | Gollob Jared | Chief Medical Off | — | $9.13M |
| 8 | Esposito Pamela | Dir | — | $3.05M |
| 9 | Goodman Noah | Chief Business Off | — | $2.22M |
| 10 | Ridloff Elena | Dir | — | $1.29M |
Transactions 19
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-05-27 17:50 | 2026-05-26+ | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale | $79.92 | -17.2K | 44.0K | -28% | -$1.37M |
| DMT | 2026-04-24 16:30 | 2026-04-22 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | M - OptEx | $39.06 | +300 | 61.5K | +0.5% | +$11.7K |
| DT | 2026-04-24 16:30 | 2026-04-22 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale+OE | $90.00 | -300 | 61.2K | -0.5% | -$27.0K |
| DMT | 2026-04-16 18:30 | 2026-04-14+ | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | M - OptEx | $34.41 | +6,551 | 62.5K | +12% | +$225.4K |
| DMT | 2026-04-16 18:30 | 2026-04-14+ | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale+OE | $90.00 | -6,551 | 61.2K | -10% | -$589.6K |
| DMT | 2026-04-01 19:00 | 2026-03-31+ | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | M - OptEx | $29.64 | +22.2K | 75.8K | +41% | +$659.2K |
| DMT | 2026-04-01 19:00 | 2026-03-31+ | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale+OE | $85.43 | -22.2K | 61.2K | -27% | -$1.90M |
| DMT | 2026-03-25 | 2026-03-23+ | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | M - OptEx | $29.64 | +109.1K | 152.5K | +252% | +$3.23M |
| DMT | 2026-03-25 | 2026-03-23+ | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale+OE | $78.02 | -116.0K | 61.2K | -65% | -$9.05M |
| DT | 2026-03-11 | 2026-03-11 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | M - OptEx | $43.50 | +20.0K | 93.8K | +27% | +$870.0K |
| DMT | 2026-03-11 | 2026-03-11 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale+OE | $83.30 | -25.8K | 68.1K | -27% | -$2.15M |
| DM | 2026-03-04 | 2026-03-02+ | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale | $86.54 | -5,958 | 79.2K | -7% | -$515.6K |
| D | 2026-03-04 | 2026-03-02 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | A - Grant | $0.00 | +12.6K | 79.8K | +19% | $0 |
| 2025-05-23 | 2025-05-23 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale | $29.30 | -2,575 | 66.4K | -4% | -$75.4K | |
| DM | 2025-03-03 | 2025-03-03 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale | $30.45 | -1,383 | 67.8K | -2% | -$42.1K |
| D | 2025-03-03 | 2025-03-03 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | A - Grant | $0.00 | +25.0K | 69.2K | +57% | $0 |
| 2024-05-23 | 2024-05-23 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | S - Sale | $34.99 | -2,575 | 44.2K | -6% | -$90.1K | |
| D | 2024-03-04 | 2024-03-01 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | A - Grant | $0.00 | +13.4K | 46.8K | +40% | $0 |
| D | 2023-05-22 | 2023-05-22 | KYMR | Kymera Therapeutics, Inc. | Chadwick Jeremy G | COO | A - Grant | $0.00 | +33.3K | 33.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations